A proposal to part with diagnosing a tumor entity recognized for nearly a century naturally will be critically questioned. Such happened following our paper entitled "Farewell to Oligoastrocytomas" [3] . Before commenting on the responses by Wilcox et al. and Huse et al. [1, 4] , we would like to point at the current practice. The frequency of the diagnosis "oligoastrocytoma" varies from essentially zero to up to 80 % of the diagnoses made for diffusely infiltrating gliomas-depending on the diagnosing institution. As a consequence, our clinical partners appear less interested in our differentiation among astrocytoma, oligoastrocytoma or oligodendroglioma-they ask: "Does it carry a 1p/19q codel or does it not". This association has indeed been shown in many clinical studies to be of significant clinical relevance. This tight association of clinical and molecular genetic parameters is a stringent argument for an attempt to separate the "oligoastrocytomas" primarily on molecular grounds into two subgroups. Done so, there is close to nothing left to distinguish these subgroups from astrocytoma on the one and oligodendroglioma on the other side. Of course, and likely no tumor entity can be exempted here, we will detect a small fraction of tumors demonstrating overlapping molecular features.
Wilcox et al. present in their response letter two cases and very convincingly demonstrate in one of them such overlapping molecular features and we congratulate this nice work. The evidence provided for their second case appears to rely mainly on immunohistochemistry presented for single cells only and we think it is in need for further analysis to fully support the claim.
